Control of HIV replication by interactions between SF3B1 and Tat

通过 SF3B1 和 Tat 之间的相互作用控制 HIV 复制

• 批准号: 10468266
• 负责人: George Kyei
• 金额: $ 19.67万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-11 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10468266
• 关键词: Affect; Alanine; Amino Acids; Binding; Binding Proteins; Biological Assay; C-terminal; CD4 Positive T Lymphocytes; Cells; Chronic Disease; Complement; Complex; Data; Drug resistance; Electrophoretic Mobility Shift Assay; Engineering; Environment; Enzymes; Future; Genetic Transcription; Goals; HIV; HIV Infections; HIV therapy; HIV-1; Histones; Immunoprecipitation; In Vitro; Integrase Inhibitors; Life Cycle Stages; Luciferases; Mammalian Cell; Measures; Mediating; Methylation; Modeling; Mutagenesis; Neural Tube Defects; Nuclear; Pathway interactions; Physiological; Play; Proteins; RNA; RNA Polymerase II; RNA Splicing; Resistance; Role; Scanning; Signal Transduction; Surface; System; Technology; Testing; Therapeutic; Therapeutic Intervention; Viral; Viral Proteins; Weight Gain; Work; adverse drug reaction; antiretroviral therapy; base; chromatin immunoprecipitation; cyclin T1; experience; fight against; genetic manipulation; in vivo; inhibitor; interest; knock-down; luminescence; macrophage; molecular domain; monocyte; mutant; nanoluciferase; neuropsychiatric disorder; new therapeutic target; novel; pathogen; promoter; protein protein interaction; targeted treatment; tat Protein; therapeutic target

PROJECT SUMMARY Antiretroviral therapy (ART) has transformed HIV into a manageable non-fatal chronic disease. However, significant challenges remain with increasing drug resistance and adverse drug reactions. Therefore, there is an urgent need to identify novel therapeutic targets with unique mechanisms of action to sustain the gains of ART. HIV transcription represents a vital part of the viral life cycle that has not been successfully targeted for therapy. We recently discovered that an interaction between the essential viral protein Tat and splicing factor 3B subunit 1 (SF3B1) is required for HIV transcription. The primary goal of this project is to define the role played by the interaction between Tat and SF3B1 in HIV transcription. The long term objective is to identify compounds that can block this interaction and therefore HIV replication. We hypothesize that Tat-mediated HIV transcription requires Tat to interacts with SF3B1 and that this interaction, when blocked will inhibit HIV replication. Our specific aims are: Aim 1: Identify the molecular domains of Tat-SF3B1 interactions required for HIV-1 transcription. We have shown that Tat and SF3B1 interact, and that this interaction requires the C-terminal portion of Tat. However, the specific domains of Tat or SF3B1 required for this interaction are unknown. First, we will use mutagenesis, along with in-vitro and in-vivo protein binding studies to narrow down the residues of Tat and the domain of SF3B1 required for the interaction. Second, we will perform in-vivo alanine scanning to better define the interaction surfaces for the two binding domains. The effect of alanine substitutions will be quantified with the NanoLuc® Binary Technology (NanoBiT) split luciferase complementation protein: protein interaction system. We will also perform Tat-SF3B1 immunoprecipitations and transcription assays in primary CD4+ T cells and monocyte-derived macrophages (MDMs) to ascertain the physiological relevance of our findings. Aim 2: Define the specific role of SF3B1 in Tat-mediated HIV-1 transcription. We showed that depletion of SF3B1 abrogates Tat-mediated HIV transcription, but the exact mechanism for SF3B1 actions on HIV transcription is unknown. SF3B1 interacts with Tat, the nuclear inhibitor of PP1 (NIPP1), and is also known to methylate HIV transcription-activating histone H3K36me3. Therefore, we hypothesize that SF3B1 may control HIV transcription through one or more of these pathways in primary CD4+T cells, MDMs and HIV latency models. First, we will use RNA Immunoprecipitation (RNAIP) and fluorescent electrophoretic mobility shift assay (fEMSA) to quantify the effects of SF3B1 on Tat/TAR interactions. Second, we will determine how SF3B1 influences Tat methylation as well as the occupancy of the HIV promoter by H3K36me3. Finally we will determine if Tat-SF3B1 interactions plays a role in NIPP1-mediated inhibition of HIV transcription. This work will be highly significant to further the understanding of Tat-mediated HIV transcription and define a potential therapeutic target for HIV.

项目摘要 抗腹腔治疗（ART）已将HIV转化为 耐药性和不良药物反应的增加仍然存在重大挑战。 迫切需要通过独特的作用机制来识别新型的治疗靶标，以维持艺术。 HIV转录代表了病毒生命周期的重要组成部分，尚未成功针对治疗。 我们最近发现了必需病毒蛋白TAT与剪接因子3B亚基之间的相互作用 HIV转录需要1（SF3B1）。 该项目的主要目标是定义艾滋病毒中Tat和SF3B1之间的相互作用所起的作用 转录。 复制。我们假设Tat介导的HIV转录需要与SF3B1相互作用 这种相互作用，当被阻止时会抑制艾滋病毒的复制。 AIM 1：确定HIV-1转录所需的TAT-SF3B1相互作用的分子结构域 已经表明TAT TAT SF3B1相互作用，并且相互作用需要TAT的C末端部分。 相互作用所需的TAT或SF3B1的特定域是未知的。 以及体内和体内蛋白质的结合研究与TAT的长 互动所需的SF3B1。 两种结合域的相互作用表面将用丙氨酸的效果进行量化。 Nanoluc®二进制技术（NANOBIT）分裂荧光素酶社区蛋白质：蛋白质相互作用系统。 我们还将在一级CD4+ T细胞中执行TAT-SF3B1免疫沉淀和转录测定 单核细胞衍生的巨噬细胞（MDMS）确定我们发现的生理相关性。 AIM 2：定义SF3B1在TAT介导的HIV-1转录中的特定作用。 SF3B1废除了TAT介导的HIV转录，但SF3B1对HIV的确切机制 转录是未知的。 甲基化HIV转录激活组蛋白H3K36Me3。 通过主要CD4+T细胞，MDM和HIV潜伏期模型中的一个或多个途径的HIV转录。 首先，我们将使用RNA Imunoprecipitation（RNAIP）和荧光电泳迁移率转移测定法（FEMSA） 为了量化SF3B1对TAT/TAR相互作用的影响。 H3K36me3作为HIV启动子的甲基化。 相互作用在NIPP1介导的侵入式转录中起作用。 这项工作对于进一步了解TAT介导的HIV转录并定义A将非常重要 艾滋病毒的潜在治疗靶点。